Silexion Therapeutics Corp (SLXNW) Financial Statements (2026 and earlier)

Company Profile

Business Address 12 ABBA HILLEL ROAD
RAMAT GAN, 5250606
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5,991,0001,187,000
Cash and cash equivalent5,991,0001,187,000
Restricted cash and investments27,00035,000
Prepaid expense570,000966,000
Other current assets49,00062,000
Total current assets:6,637,0002,250,000
Noncurrent Assets
Operating lease, right-of-use asset412,000530,000
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization25,00030,000
Deposits noncurrent assets84,0005,000
Restricted cash and investments57,00048,000
Total noncurrent assets:578,000613,000
TOTAL ASSETS:7,215,0002,863,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,666,0001,571,000
Accounts payable787,000929,000
Accrued liabilities879,000642,000
Other undisclosed current liabilities1,092,0001,952,000
Total current liabilities:2,758,0003,523,000
Noncurrent Liabilities
Liabilities, other than long-term debt286,000368,000
Operating lease, liability286,000368,000
Other undisclosed noncurrent liabilities 1,568,0002,961,000
Total noncurrent liabilities:1,854,0003,329,000
Total liabilities:4,612,0006,852,000
Equity
Equity, attributable to parent2,603,000(3,989,000)
Common stock42,0002,000
Additional paid in capital57,727,00039,263,000
Accumulated deficit(55,166,000)(43,254,000)
Total equity:2,603,000(3,989,000)
TOTAL LIABILITIES AND EQUITY:7,215,0002,863,000

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
Gross profit:(419,000)(3,939,000)
Operating expenses(11,632,000)(12,571,000)
Other undisclosed operating income419,0003,939,000
Operating loss:(11,632,000)(12,571,000)
Nonoperating income140,000254,000
Gain, foreign currency transaction, before tax127,000247,000
Loss from continuing operations before equity method investments, income taxes:(11,492,000)(12,317,000)
Other undisclosed loss from continuing operations before income taxes(417,000)(4,192,000)
Loss from continuing operations before income taxes:(11,909,000)(16,509,000)
Income tax expense(3,000)(10,000)
Net loss:(11,912,000)(16,519,000)
Net loss attributable to noncontrolling interest  (76,000)
Other undisclosed net income attributable to parent  76,000
Net loss attributable to parent:(11,912,000)(16,519,000)
Other undisclosed net income available to common stockholders, basic23,824,00032,962,000
Net income available to common stockholders, diluted:11,912,00016,443,000

Comprehensive Income (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
Net loss:(11,912,000)(16,519,000)
Comprehensive loss:(11,912,000)(16,519,000)
Comprehensive loss, net of tax, attributable to noncontrolling interest  (76,000)
Comprehensive loss, net of tax, attributable to parent:(11,912,000)(16,595,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios